Vir Biotechnology, Inc. (VIR)

Every figure this model derived for VIR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,087,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 528,593,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 573,739,000 AssetsCurrent 2026-06-30
current liabilities 94,961,000 LiabilitiesCurrent 2026-06-30
equity 982,493,000 StockholdersEquity 2026-06-30
ocf -202,506,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 303,227,000 Revenues 2026-06-30
sbc 47,040,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VIR on one particular measure came for.

RatioValue
cash operating margin-73.09
current ratio6.04
current ratio reported6.04
deferred revenue growth-100.0
dilution pct1.67
fcf margin-67.14
growth cv2.14
operating margin-92.4
owner earnings margin-82.66
revenue growth1495.93
revenue growth per share1469.72
roic-48.77
rule of 401403.53
sbc pct revenue15.51

What to be careful about

What this model itself distrusts about VIR's figures. Written by the derivation as it ran, not added afterwards.